The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression
Top Cited Papers
Open Access
- 26 April 2025
- journal article
- review article
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-12
Abstract
The irreversible degeneration of dopamine neurons induced by α-synuclein (α-syn) aggregation in the substantia nigra is the central pathological feature of Parkinson's disease (PD). Neuroimaging and pathological autopsy studies consistently confirm significant iron accumulation in the brain of PD patients, suggesting a critical role for iron in disease progression. Current research has established that iron overload induces ferroptosis in dopaminergic neurons, evidence indicates that the impact of iron on PD pathology extends beyond ferroptosis. Iron also plays a regulatory role in modulating α-syn, affecting its aggregation, spatial conformation, post-translational modifications, and mRNA stability. Iron-induced α-syn aggregation can contribute to dopaminergic neurodegeneration through additional mechanisms, potentially creating a feedback loop in which α-syn further enhances iron accumulation, thus perpetuating a vicious cycle of neurotoxicity. Given α-syn’s intrinsically disordered structure, targeting iron metabolism presents a promising therapeutic strategy for PD. Therefore, the development of iron chelators, alone or in combination with other therapeutic drugs, may offer a beneficial approach to alleviating PD symptoms and slowing disease progression.Keywords
This publication has 123 references indexed in Scilit:
- Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson's Disease TherapyAdvanced Materials, 2024
- Continuous Subcutaneous Foslevodopa‐Foscarbidopa in Parkinson's Disease: A Mini‐Review of Current Scope and Future OutlookMovement Disorders Clinical Practice, 2024
- Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson’s diseaseEuropean Radiology, 2023
- Initiation and progression of α-synuclein pathology in Parkinson’s diseaseCellular and Molecular Life Sciences, 2022
- Benefits of Iron Chelators in the Treatment of Parkinson’s DiseaseNeurochemical Research, 2021
- The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s diseaseJournal of Neural Transmission, 2020
- Parkinson’s disease and ironJournal of Neural Transmission, 2020
- Role and Mechanism of Microglial Activation in Iron-Induced Selective and Progressive Dopaminergic NeurodegenerationMolecular Neurobiology, 2013
- Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson DiseaseArchives of Neurology, 2011
- Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body diseaseAnnals of Neurology, 1992